Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: Superior Efficacy and Posttreatment Prophylaxis against Multidrug-Resistant *Plasmodium falciparum* and *Plasmodium vivax* Malaria


1National Institute of Health Research and Development and 2Directorate General of Communicable Disease Control and Environmental Health, Ministry of Health, Jakarta; 3Menzies School of Health Research–National Institute of Health Research and Development Malaria Research Program and 4District Ministry of Health, Timika; and 5Public Health and Malaria Control Department, PT Freeport, and 6International SOS, Tembagapura, Papua, Indonesia; 7International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia; and 8Centre for Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

(See the editorial commentary by Plowe on pages 1075–7)

**Background.** Antimalarial drug resistance is now well established in both *Plasmodium falciparum* and *Plasmodium vivax*. In southern Papua, Indonesia, where both strains of plasmodia coexist, we have been conducting a series of studies to optimize treatment strategies.

**Methods.** We conducted a randomized trial that compared the efficacy and safety of dihydroartemisinin-piperaquine (DHP) with artesunate-amodiaquine (AAQ). The primary end point was the overall cumulative parasitological failure rate at day 42.

**Results.** Of the 334 patients in the evaluable patient population, 185 were infected with *P. falciparum*, 80 were infected with *P. vivax*, and 69 were infected with both species. The overall parasitological failure rate at day 42 was 45% (95% confidence interval [CI], 36%–53%) for AAQ and 13% (95% CI, 7.2%–19%) for DHP (hazard ratio [HR], 4.3; 95% CI, 2.5–7.2; *P* <.001). Rates of both recrudescence of *P. falciparum* infection and recurrence of *P. vivax* infection were significantly higher after receipt of AAQ than after receipt of DHP (HR, 3.4 [95% CI, 1.2–9.4] and 4.3 [95% CI, 2.2–8.2], respectively; *P* <.001). By the end of the study, AAQ recipients were 2.95-fold (95% CI, 1.2- to 4.9-fold) more likely to be anemic and 14.5-fold (95% CI, 3.4- to 61-fold) more likely to have carried *P. vivax* gametocytes.

**Conclusions.** DHP was more effective and better tolerated than AAQ against multidrug-resistant *P. falciparum* and *P. vivax* infections. The prolonged therapeutic effect of piperaquine delayed the time to *P. falciparum* reinfection, decreased the rate of recurrence of *P. vivax* infection, and reduced the risk of *P. vivax* gametocyte carriage and anemia.

Antimalarial drug resistance poses a significant threat to communities where malaria is endemic. Although chloroquine- and sulfadoxine-pyrimethamine–resistant strains of *Plasmodium falciparum* emerged more than 50 years ago, chloroquine resistance in *P. vivax* was described relatively recently [1, 2]. Chloroquine-resistant strains of *P. vivax* have now been documented across Asia [3–7] and in South America [8, 9]. Despite these reports, few studies have addressed suitable treatment regimens for infections with such resistant isolates [10]. In Indonesia, the efficacy of amodiaquine is superior to that of chloroquine, but in regions where high levels of chloroquine resistance predominate, day 28 failure rates exceed 25% [11]. Alternative agents, such as mefloquine, halofantrine, and atovaquone-proguanil, are effective but expensive, and they may be
poorly tolerated, particularly among young children [10, 12].

Artemisinin combination therapy (ACT) is now widely advocated for the treatment of *P. falciparum* infection, and in accordance with this policy, the Indonesian Ministry of Health has started the transition to ACT deployment as part of an integrated malaria-control strategy. Although regimens of amodiaquine plus artesunate (AAQ) have been deployed as first-line therapy for *P. falciparum* infection, their efficacy against chloroquine-resistant *P. vivax* infection has not been established.

In Papua, Indonesia, where resistance has emerged among both *P. falciparum* and *P. vivax*, we have been conducting a series of drug trials to optimize treatment strategies [3, 11, 13]. In the present study, we compare the safety and efficacy of dihydroartemisinin-piperaquine (DHP) with those of AAQ for the treatment of patients with malaria who presented to rural clinics with *P. falciparum* and/or *P. vivax* infection.

**MATERIALS AND METHODS**

**Study site.** The study was performed at 2 rural clinics west of the Timika in southern Papua, Indonesia. This lowland region is partly forested, with *Anopheles punctulatus* responsible for unstable malaria transmission [14, 15]. The annual incidence of malaria in the region is 938 cases per 1000 persons per year (ratio of transmission [14, 15]). The annual incidence of malaria in the region is 938 cases per 1000 persons per year (ratio of transmission [14, 15]; unpublished data). Local protocols recommend that all patients with patent infections to *P. falciparum*, *P. vivax*, or both, and fever or a history of fever or *P. falciparum*, *P. vivax*, or both) and fever or a history of fever and/or *P. vivax*, in the region is 938 cases per 1000 persons per year (ratio of transmission [14, 15]).

**Study design.** The study was a prospective, open-label, randomized comparison of AAQ with DHP for the treatment of uncomplicated symptomatic malaria. The study was based on the 2001 World Health Organization (WHO) in vivo antimalarial drug susceptibility protocol [16] that was modified to include mixed infections and any level of parasitemia. Patients for whom therapy failed were offered an alternative to their primary treatment and were observed for an additional 42 days. Patients who refused further follow-up received unsupervised re-treatment, in accordance with local policy, with quinine (10 mg of salt per kg of body weight orally 3 times per day for 7 days) and with additional doxycycline (100 mg per day for 7 days) if they were >8 years of age and not pregnant.

**End points.** The analysis of efficacy was conducted using a modified intention-to-treat analysis that included all patients.
who fulfilled the enrollment criteria. The primary end point was the overall risk of reappearance of any parasitemia during the 42-day follow-up period. Secondary end points included the risk of reappearance of *P. falciparum* (further divided into the risks of recrudescence and reinfection) and the recurrence of *P. vivax* infection. Other secondary end points assessed were the proportion of parasitemic patients on days 1, 2, and 3; posttreatment gametocyte carriage; and hematological recovery.

**Sample size.** The original sample size of 400 patients had 80% power and 95% confidence to detect a 12% difference in the primary end point. An interim analysis was performed by an independent data safety monitoring committee after 3 months, and in view of the statistical difference in efficacy between treatment groups, the committee recommended that patient recruitment be stopped. At this stage, 340 patients had been enrolled.

**Statistical analysis.** Data were double-entered and validated using EpiData software, version 3.02 (EpiData Association), and analysis was performed using SPSS for Windows, version 14 (SPSS). The Mann-Whitney *U* test was used for nonparametric comparisons, and Student’s *t* test or 1-way analysis of variance was used for parametric comparisons. Proportions were examined by χ² test with Yates’ correction or by Fisher’s exact test.

Efficacy end points were assessed by survival analysis, in which the cumulative risk of failure was calculated by the Kaplan Meier product limit formula and compared by the Mantel-Haenszel log rank test. In addition, treatments were compared, and the hazard ratio (HR) was calculated after stratifying for the initial infecting parasite species using Cox’s proportional hazards model. Data were censored for patients who were lost to follow-up or, for secondary end points, represented a different outcome, and were regarded as not experiencing treatment failure. Patients with recurrent vomiting or adverse drug effects who required early termination of treatment and the administration of rescue therapy were regarded as having experienced therapeutic failure.

In patients with *P. falciparum* (alone or mixed) in both the initial and recurrent parasitemia, reinfections and recrudescent infections were determined by PCR on the basis of polymorphisms in MSP-1, MSP-2, and GLURP, as described elsewhere [18]. Of the 18 *P. falciparum* paired treatment failures, there were 4 cases (22%) in which PCR was unavailable or the results were indeterminate. In these cases, the cure rates were adjusted on the basis of temporal probabilities of recrudescence versus reinfection, as determined by comparison with patients with complete data.

Gametocyte carriage was assessed by calculating person-gametocyte week rates as a measure of transmission potential [19]. The adverse events reported were commonly associated with acute malaria; thus, comparison between treatment groups was made for patients who did not have the symptom at the time of admission and who developed the symptom after commencement of antimarial treatment.

**Ethics.** The study was approved by the ethics committees of the National Institute of Health Research and Development, Indonesian Ministry of Health (Jakarta, Indonesia), and of the Menzies School of Health Research (Darwin, Australia). Written informed consent was obtained from adult patients and from parents of enrolled children. The trial was registered with the clinical trials Web site (http://www.clinicaltrials.gov/ct) as NCT 00157885.

**RESULTS**

During the period from July 2005 through December 2005, a total of 1310 patients with uncomplicated malaria were treated at the recruitment clinics. Six protocol violations (4 in the AAQ arm and 2 in the DHP arm) were identified within 24 h; patients were offered alternative treatment and excluded from further analysis (figure 1). Of the remaining 334 patients, 185 patients (55%) had *P. falciparum* infection alone, 114 (34%) had *P. vivax* infection alone, and both species were present in 35 (10%).
Baseline characteristics were similar between treatment groups (table 1). Follow-up to day 42 or to the day of treatment failure was achieved for 134 (81%) of the 166 patients treated with AAQ and for 132 (79%) of the 168 treated with DHP.

**Early therapeutic response.** Five patients (3%) in the AAQ arm and 1 patient (0.6%) in the DHP arm were unable to tolerate their medication because of recurrent vomiting and were given oral or intravenous quinine. Early clinical deterioration that required hospitalization was observed in 2 patients within 4 h after receipt of DHP; both were transferred to the hospital, treated with intravenous quinine, and made unremarkable recoveries. Of the remaining patients, there were no differences between the treatment groups with regard to the rate of parasite or fever clearance time. Within 48 h, 318 (99%) of 321 patients were aparasitemic, and 318 (99%) were afebrile.

**Late therapeutic response.** In total, 66 patients had a recurrent parasitemia during the follow-up period (figure 1); 29 (46%) of 63 of these patients were symptomatic, 5 (8%) of 63 had documented fever, and 11 (32%) of 34 were anemic (defined as a hemoglobin concentration <10 g/dL). There were no significant differences in these rates between treatment groups or between parasite species.

The cumulative risk of overall parasitological failure by day 42 was 45% (95% CI, 36%–53%) after AAQ treatment, compared with 13% (95% CI, 7.2%–19%) after DHP treatment (HR, 4.3; 95% CI, 2.5–7.2; P < .001). Compared with AAQ recipients, patients treated with DHP had a lower risk of failure for all of the secondary end points assessed (table 2 and figure 2).

**Gametocyte carriage after treatment.** At the time of admission, *P. falciparum* gametocytes were present in 23 (10%) of 220 patients with *P. falciparum* infection or mixed infection, with no differences in subsequent carriage rates between treatment groups (overall rate, 12.1 cases per 1000-person weeks). *P. vivax* gametocytes at the time of admission were present in 113 (76%) of 149 patients with *P. vivax* infection (alone or mixed). During follow-up, *P. vivax* gametocytemia was always associated with the recurrence of *P. vivax* asexual stages and was significantly less likely to occur among DHP recipients (2.5 cases per 1000-patient weeks) than among AAQ recipients (36.5 cases per 1000-patients weeks; rate ratio, 14.5; 95% CI, 3.4–61; P < .001).

**Hematological recovery.** Although there was no significant difference in hemoglobin levels between treatment groups at

### Table 1. Patient characteristics at baseline in a study of dihydroartemisinin-piperaquine (DHP) versus artesunate-amodiaquine (AAQ) as posttreatment prophylaxis against multidrug-resistant *Plasmodium falciparum* and *Plasmodium vivax* infection.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>AAQ arm</th>
<th>DHP arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients in the evaluable population</td>
<td>166</td>
<td>168</td>
</tr>
<tr>
<td>Infecting species at time of study enrollment</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>P. falciparum</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. (%) of patients</td>
<td>91 (55)</td>
<td>94 (56)</td>
</tr>
<tr>
<td>Geometric mean parasite load per μL (95% CI)</td>
<td>4867 (3430–6908)</td>
<td>5514 (4117–7386)</td>
</tr>
<tr>
<td>Parasite load &gt;1000 parasites/μL&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>75 (82)</td>
<td>83 (88)</td>
</tr>
<tr>
<td><em>P. vivax</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. (%) of patients</td>
<td>60 (36)</td>
<td>54 (32)</td>
</tr>
<tr>
<td>Geometric mean parasite load per μL (95% CI)</td>
<td>2575 (1669–3973)</td>
<td>1504 (979–2308)</td>
</tr>
<tr>
<td>Parasite load &gt;400 parasites/μL&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>52 (87)</td>
<td>40 (76)</td>
</tr>
<tr>
<td>Mixed infection</td>
<td>15 (9)</td>
<td>20 (12)</td>
</tr>
<tr>
<td>Geometric mean parasite load per μL (95% CI)</td>
<td>4072 (2103–7885)</td>
<td>4764 (2393–9483)</td>
</tr>
<tr>
<td>Parasite load &gt;400 parasites/μL&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>15 (100)</td>
<td>19 (95)</td>
</tr>
<tr>
<td>Male sex</td>
<td>92 (55)</td>
<td>99 (59)</td>
</tr>
<tr>
<td>Weight, median kg (range)</td>
<td>43 (6.6–72)</td>
<td>46 (8–85)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median years (range)</td>
<td>15 (1–60)</td>
<td>17 (1–56)</td>
</tr>
<tr>
<td>&lt;5 years</td>
<td>37 (22)</td>
<td>30 (18)</td>
</tr>
<tr>
<td>5–14 years</td>
<td>46 (28)</td>
<td>46 (27)</td>
</tr>
<tr>
<td>&gt;14 years</td>
<td>83 (50)</td>
<td>92 (55)</td>
</tr>
<tr>
<td>Temperature &gt;37.5°C</td>
<td>50 (30)</td>
<td>57 (34)</td>
</tr>
<tr>
<td>History of malaria in previous month</td>
<td>27 (16)</td>
<td>31 (19)</td>
</tr>
<tr>
<td>Hemoglobin concentration, mean g/dL ± SD</td>
<td>10.8 ± 2.6</td>
<td>11.1 ± 2.6</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>111 (67)</td>
<td>123 (73)</td>
</tr>
</tbody>
</table>

**NOTE.** Data are no. (%) of patients, unless otherwise indicated.
the time of admission, the rates of anemia at days 7 and 28 were significantly higher in AAQ recipients (figure 3). After stratifying by the presence of anemia at the time of admission, the relative risk (RR) of anemia associated with AAQ at day 7 was 1.65 (95% CI, 1.04–1.85; \( P = .04 \)), and at day 28, it was 2.95 (95% CI, 1.2–4.9; \( P = .019 \)).

**Tolerability.** In total, 13 (7.8%) of 166 patients who received AAQ vomited at least 1 dose of medication, compared with 7 (4.2%) of 168 patients who received DHP (\( P = .2 \)). On days 1 and 2, AAQ recipients were more likely than DHP recipients to report nausea (22 [27%] of 90 vs. 16 [8.5%] of 188; \( P = .004 \)), vomiting (27 [23%] of 117 vs. 11 [10.7%] of 103; \( P = .02 \)), and anorexia (20 [36%] of 55 vs. 7 [13%] of 56; \( P = .007 \)). By day 7 and thereafter, there were no reported differences between groups in symptoms elicited.

Serious adverse events were noted in 3 patients. Two adults developed recurrent vomiting on day 3 after completion of a course of AAQ, requiring admission to hospital and administration of intravenous fluids and antiemetics. Both made a full recovery and were discharged from the hospital within 24 h. A 29-year-old man with *P. falciparum* infection who was treated with AAQ developed bilateral cerebellar signs (truncal ataxia and intention tremor) on day 7. Neurological examination findings were otherwise unremarkable, and the patient’s symptoms resolved over the subsequent 8 days. On day 21, he had a recurrence of *P. falciparum* infection, which was re-treated with DHP, without further recurrence of infection, symptoms, or cerebellar signs over the subsequent 42 days.

**Re-treatment.** In total, 66 patients had recurrent parasitemia during follow-up, of whom 14 refused additional follow-up and received unsupervised re-treatment with quinine, with or without doxycycline. Of the remaining patients, 46 were re-treated with DHP (26 patients with *P. vivax* infection, 14 with *P. falciparum* infection, and 6 with mixed infection). The overall cumulative failure rate among these patients was 29% (95% CI, 9.9%–49%), with 5 patients having recurrent *P. vivax* infection and 1 patient having reinfection with *P. falciparum*. Six patients were re-treated with AAQ, of whom 1 was lost to follow-up on day 21; the rest of these patients had an additional recurrence of parasitemia (3 cases were due to *P. vivax*, and 2 were mixed infections).

**DISCUSSION.**

In the past decade, an increasing awareness of the extent and impact of antimalarial drug resistance has stimulated renewed interest in comparative drug trials to rationalize treatment policies. Most of these studies have focussed on *P. falciparum* infection, with virtually no comparative efficacy data addressing the management of chloroquine-resistant *P. vivax* malaria posing a significant threat to the 250 million people infected each year [21].

The WHO recommends the use of ACTs for uncomplicated *P. falciparum* malaria to improve antimalarial efficacy and minimize the risk of selection of drug-resistant parasites. In practice, the infecting species is only correctly identified in a minority of infections before the commencement of treatment; thus, in Asia and South America, where *P. vivax* often accounts for >50% of cases of malaria, other species will be frequently treated with ACT. The efficacy of ACT against *P. vivax*—in particular, against chloroquine-resistant strains—is, therefore, an important consideration when optimizing antimalarial protocols. In the present study, we have attempted to mirror local
primary health care prescription practices, and we enrolled patients of all ages with all degrees of parasitemia and combinations of species.

The early therapeutic response following both treatments was rapid, and within 48 h, almost all patients had cleared their peripheral parasitemia and were afebrile. During subsequent follow-up, recurrent parasitemia occurred in only 13% of patients treated with DHP, whereas it occurred in 45% of those treated with AAQ ($P < .001$). Although the risk of true recrudescence with $P. falciparum$ was $< 5\%$ after receipt of DHP—similar to that found in other areas where multidrug-resistant $P. falciparum$ is common [22–27]—the rates of recrudescence and reinfection involving $P. falciparum$ were significantly higher after receipt of AAQ treatment (adjusted HR, 4 and 3.8, respectively).

The difference in the risk of recurrence was even more marked for $P. vivax$ infection (adjusted HR, 4.3). Such recurrences can be attributed to either recrudescence, reinfection, or relapse from dormant liver-stage infection [28], although we were unable to distinguish between these causes. In Papua and equatorial regions, relapse of $P. vivax$ infection occurs in up to 60% of patients [29], with the first relapse occurring at $\sim 21$ days [29]. Because neither artemisinin, piperaquine, nor amodiaquine is active against the hypnozoite stages of $P. vivax$ [30], the discrepancy between AAQ and DHP regimens is likely to have arisen as a result of a combination of the reduced efficacy of amodiaquine against asexual parasites and its shorter terminal elimination half-life ($\sim 18$ days), compared with the half-life of piperaquine (28–35 days) [31, 32]. The posttreatment prophylaxis associated with the long half-life of piperaquine reduces both relapses of $P. vivax$ infection and reinfections with either species. It is possible that a higher dosage of primaquine (0.5 mg/kg per day) could have further reduced the risk of relapse of $P. vivax$ infection; however, in reality, patients rarely adhere to a 14-day regimen. Posttreatment prophylaxis, therefore, provides the only practical means currently available for delaying these relapses. The delays in relapse and reinfection conferred by DHP gave patients a longer period free from symptomatic malaria, allowing for a greater time for hematological recovery and significantly reducing gametocyte carriage and the transmission potential to the mosquito vector.

A major concern with deploying antimalarial drugs that have a long half-life is that they will facilitate the selection of drug-resistant parasites. Although it is hoped that combination with an artemisinin derivative will reduce the risk of de novo selective transmission, once drug-resistant strains do emerge, selective transmission in the prolonged subtherapeutic tail of piperaquine is likely to encourage the spread of resistance. Therefore, careful monitoring of in vivo and in vitro antimalarial efficacy must remain a priority.

There were also significant differences in the tolerability between the treatment regimens. Patients treated with AAQ were 2–3-fold more likely to develop nausea, vomiting, and anorexia while receiving treatment, compared with DHP recipients. One patient developed ataxia and an intention tremor 7 days after

Figure 3. Proportion of patients with anemia. Anemia was defined as a hemoglobin concentration of <10 g/dL. Dark bars, dihydroartemisinin-piperaquine; light bars, artesunate-amodiaquine.
comprising treatment with AAQ. Cerebellar dysfunction, although rare, is a well-recognized complication of malaria [33, 34], and although cases of cerebellar dysfunction have been attributed to artemisinin neurotoxicity [35], the clinical scenario and body of evidence to date suggest that postmalaria neurological syndrome is a more plausible explanation for what occurred in our patient [33, 34, 36].

In conclusion, DHP was more efficacious and better tolerated than AAQ for the treatment of multidrug-resistant P. falciparum and P. vivax infections in Papua, Indonesia. Its coformulation, cost (US$2 per adult), and posttreatment prophylactic effect offer significant benefits over other available ACTs, making it a prime option for the management of uncomplicated malaria in this region.

Acknowledgments

We are grateful to the staff of PT Freeport Indonesia Public Health & Malaria Control Department, International SOS, and Lembaga Pengembangan Masyarakat Amungme Kamoro for support and technical assistance. We thank Mauritz Okesery, Rosmini, Buhari, Alan Brockman, Kim Piera, Ferryanto Chafeline, and Budi Prasetyorini for their support and technical assistance. We are also grateful to Morrison Bethea and PT Freebangan Masyarakat Amungme Kamoro for support and technical assistance. We are also grateful to Morrison Bethea and PT Freebangan Masyarakat Amungme Kamoro for support and technical assistance. We are also grateful to Morrison Bethea and PT Freebangan Masyarakat Amungme Kamoro for support and technical assistance. We are also grateful to Morrison Bethea and PT Freebangan Masyarakat Amungme Kamoro for support and technical assistance.

Financial support. Wellcome Trust–National Health and Medical Research Council (NHMRC; Wellcome Trust International Collaborative Research Grant GR071614MA–NHMRC ICRG ID 283321). N.A. is supported by an NHMRC Practitioner Fellowship. R.P. is funded by a Wellcome Trust Career Development Award, affiliated with the Wellcome Trust–Mahidol University–Oxford Tropical Medicine Research Programme (074637).

Potential conflicts of interest. All authors: no conflicts.

References

29. Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chlo-